Published on December 7, 2009 at 3:28 AM
Boehringer Ingelheim today announced very positive results from their
landmark RE-COVER™ study – the most advanced trial programme assessing a
novel oral anticoagulant in development for acute venous thromboemolism
(VTE) treatment – presented at the American Society of Hematology Annual
Meeting and published in the New England Journal of Medicine
online.
The oral direct thrombin inhibitor, dabigatran etexilate (150 mg
twice-daily, BID), showed equal efficacy compared to well-controlled
warfarin at preventing recurrent VTE (2.4% vs. 2.1%, hazard ratio 1.10,
95% CI 0.65 to 1.84, p<0.001 for prespecified non-inferiority margin).
For safety, dabigatran etexilate demonstrated a significant 37%
reduction in major or clinically relevant non-major bleeding>
“The results of RE-COVER™ are a long-awaited breakthrough in the
treatment of VTE; not only does dabigatran etexilate offer an effective
therapy to prevent recurrent VTE it does so with less bleeding than
warfarin.” commented Dr Sam Schulman, Principal Investigator,
Department of Medicine, McMaster University, Hamilton, Canada. “Warfarin
is a highly effective therapy when well-controlled within its narrow
therapeutic range, as in clinical trials, but in the real world
sufficient control is rarely achieved and maintained, leaving patients
poorly protected from VTE or at risk of bleeding. With dabigatran, we
have a therapy that protects our patients effectively and safely,
without need for frequent laboratory monitoring and dose changes.”
SOURCE Boehringer Ingelheim
21107edf-f4af-46eb-b495-b8920b9a220f|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Anticoagulant, Breast Cancer, Cancer, Cardiovascular Disease, Coronary Heart Disease, Hematology, Heparin, Hospital, Prostate Cancer, Pulmonary Embolism, Pulmonary Hypertension, Stroke, Thrombosis, Vitamin K, Warfarin